A multiplex IHC panel lets you read several tumor states on one section instead of inferring them across serial slides. Human colorectal cancer organoids retain key architectural and molecular features of the primary tumor, which makes them a powerful system for studying tumor heterogeneity, cancer stem-like cell populations, epithelial differentiation, and epithelial–mesenchymal transition (EMT) (van de Wetering et al., Cell 2015). This case study shows how a single tyramide signal amplification (TSA) based 5-plex, 6-color multiplex IHC panel resolves all five markers on FFPE organoid sections, and lists the validated reagents behind it.
Why colon cancer organoids need a spatial multiplex IHC panel
The biology of interest in organoid models is spatial. Whether a stem-like compartment sits at the leading edge, whether differentiated and mesenchymal phenotypes segregate or intermingle, and how those states map onto epithelial architecture are questions that dissociative methods (flow, bulk expression) cannot answer. Staining one marker at a time on serial sections loses the co-registration you need to say two states occupy the same region. A single section carrying stemness, epithelial-identity, differentiation, and EMT markers together, in register with the nuclei, keeps that context intact.
How TSA builds a 5-plex multiplex IHC panel on one section
TSA-based multiplex immunohistochemistry deposits a fluorophore covalently at each antigen through HRP-catalyzed tyramide chemistry, then strips the antibody complex before the next round. Because the signal, not the antibody, stays on the tissue, the same host species (here, rabbit primaries) can be used across every cycle, and low-abundance targets gain the sensitivity that single-round immunofluorescence often can't reach on FFPE material (Yu et al., Front Oncol 2025).
Why it fits organoids: FFPE organoid sections are small, precious, and often low-input. Covalent TSA deposition plus sequential stripping lets a five-marker panel run on a single section without spectral or host-species conflicts, preserving tissue for the readout that matters.
The five markers in the mIHC panel: ALDH1A1, EpCAM, CK20, LGR5, Vimentin
The ALDH1A1 / EpCAM / CK20 / LGR5 / Vimentin combination spans stem-like, epithelial, differentiation, and mesenchymal biology in one panel. All five primaries are validated rabbit monoclonals available through BioHippo's oncology antibodies.
ALDH1A1 — cancer stem cell–associated marker (stemness)
Aldehyde dehydrogenase 1A1 activity is associated with stem-like tumor cell populations and is widely used to flag putative cancer stem-like cells. Read alongside LGR5 to cross-reference two independent stemness signals rather than relying on either alone.
EpCAM — epithelial cell adhesion molecule (epithelial identity)
EpCAM identifies epithelial tumor compartments and provides the epithelial reference frame against which stemness and mesenchymal signals are interpreted, delineating where the organoid's epithelium sits within the section.
CK20 (Cytokeratin 20) — colorectal differentiation marker
Cytokeratin 20 marks intestinal lineage and epithelial differentiation, helping distinguish differentiated compartments from stem-like ones and assess how far the organoid recapitulates colorectal identity.
LGR5 — intestinal & colorectal cancer stem cell marker
LGR5 (GPR49) marks intestinal stem cells and colorectal cancer stem-like cells, supporting evaluation of tumor-initiating capacity and stemness (Shimokawa et al., Nature 2017). Paired with ALDH1A1, it gives a two-marker view of the stem-like compartment.
Vimentin — mesenchymal / EMT marker
Vimentin is a mesenchymal intermediate filament used to detect EMT-associated and invasive phenotypes. Co-registered with the epithelial markers, it shows where cells shift toward a mesenchymal state within the same organoid.
Multiplex IHC data: five markers resolved on one organoid section
A representative 5-plex, 6-color multiplex IHC run on human colorectal cancer organoids detects all five markers plus a DAPI nuclear counterstain. The composite overlay shows the markers in spatial context; each channel can also be viewed alone to confirm compartment-specific localization.
Panel key (marker → emission channel): ALDH1A1 → 435 nm (stem-like tumor cells) · EpCAM → 488 nm (epithelial compartment) · CK20 → 525 nm (intestinal differentiation) · LGR5 → 594 nm (CRC stem-like cells) · Vimentin → 680 nm (EMT / mesenchymal) · DAPI → nuclear counterstain. Marker–fluorophore assignments reflect a representative validated run and should be confirmed and optimized for your samples.
Because the readout is spatial, the composite supports the questions organoid models are built to answer: whether stem-like and differentiated compartments segregate, whether Vimentin-positive (mesenchymal) cells localize to particular regions, and how each state maps onto the EpCAM-defined epithelium.
The multiplex IHC workflow, FFPE section to spatial analysis
- FFPE organoid preparation. Section the paraffin-embedded organoid onto charged slides and dewax. A combined one-step dewax / antigen-retrieval option streamlines this stage.
- Antigen retrieval & tissue conditioning. Retrieve epitopes and block endogenous enzyme and non-specific background to set up clean, sequential detection.
- Sequential antibody incubation & TSA staining. Run each primary in turn with HRP-based detection and TSA deposition, stripping the antibody complex between cycles so signals accumulate without host-species conflict.
- Multispectral imaging & quantitative analysis. Counterstain nuclei (DAPI), mount with antifade, and acquire on a multispectral / digital pathology system for spatial, quantitative readout.
Reagents for the colon cancer organoid mIHC panel
The five validated primaries below are stocked and orderable directly. The supporting reagents and consumables that complete the TSA workflow are available as a configured solution — request a quote and a BioHippo specialist will scope the kit, amplification reagents, and consumables to your run.
| Marker | Reagent (BioHippo) | Reactivity | Channel · Dilution |
|---|---|---|---|
| ALDH1A1 | U-Blot® ALDH1A1 Rabbit mAb (BHA21800410) | Hu · Ms · Rat | 435 nm · 1:500 |
| EpCAM | U-Blot® EpCAM Rabbit mAb (BHA21800145) | Hu · Ms · Rat | 488 nm · 1:500 |
| CK20 | U-Blot® Cytokeratin 20 Rabbit mAb (BHA21800329) | Hu · Rat | 525 nm · 1:500 |
| LGR5 | U-Blot® LGR5/GPR49 Rabbit mAb (BHA21801187) | Hu · Ms · Rat | 594 nm · 1:500 |
| Vimentin | U-Blot® Vimentin Rabbit mAb (BHA21800297) | Hu · Ms · Rat | 680 nm · 1:500 |
Supporting workflow components available by quote: the mIHC assay kit & TSA amplification reagents; HRP-conjugated secondary detection; signal blocking and stripping/recycling reagents; auxiliary reagents (deparaffinization, antigen retrieval, permeabilization, protein blocking, wash, mounting, antifade, nuclear counterstain); and consumables (charged slides, coverslips, humidity chambers, staining containers, tips). The 5-plex multiplex IHC assay kit and TSA/detection reagents are configured per project and not individually listed on the storefront — request a quote to have the full solution scoped.
What the integrated multiplex IHC panel buys you
- One spatial frame. Stemness, epithelial identity, differentiation, and EMT are read on a single section, in register with nuclei — not inferred across serial slides.
- Sensitivity on low-input FFPE. TSA amplification surfaces low-abundance markers where single-round IF often falls short.
- No host-species bottleneck. Covalent deposition plus stripping lets an all-rabbit primary panel run sequentially.
- Validated, consistent reagents. The five primaries are stocked rabbit monoclonals with defined mIHC dilutions; supporting reagents are matched to the same workflow.
- Expandable. The panel is a starting point — re-order channels or add oncology, immunology, and stem-cell targets as the question grows.
Typical applications include colon cancer organoid characterization, cancer stem cell research, tumor heterogeneity studies, EMT mechanism investigation, drug-response evaluation (Mo et al., Adv Sci 2022), and translational oncology / spatial biology.
Multiplex IHC panel — frequently asked questions
What is a multiplex IHC panel?
A multiplex IHC (mIHC) panel detects several protein markers on a single tissue section, each in its own color channel, so multiple cell states can be read in the same spatial frame. The panel here reads five markers plus a DAPI nuclear counterstain in six colors on one FFPE colorectal cancer organoid section.
Why use tyramide signal amplification (TSA) for multiplex IHC?
TSA deposits the fluorophore covalently at the antigen through HRP-catalyzed tyramide chemistry, then the antibody complex is stripped before the next cycle. Because the signal stays on the tissue rather than the antibody, the same host species (all-rabbit here) can be used across every round, and low-abundance targets gain sensitivity that single-round immunofluorescence often can't reach on FFPE material.
Can all five primary antibodies be rabbit monoclonals?
Yes. Sequential TSA multiplex IHC strips each antibody complex between cycles, so an all-rabbit panel runs without host-species cross-reactivity. All five primaries in this panel are validated rabbit monoclonals.
Which markers should a colon cancer organoid panel include?
This panel pairs two stemness markers (ALDH1A1, LGR5), an epithelial reference (EpCAM), a colorectal differentiation marker (CK20), and a mesenchymal/EMT marker (Vimentin) — spanning stem-like, epithelial, differentiated, and mesenchymal biology in one section. It is a starting point that can be re-ordered or expanded for additional targets.
Where can I get the antibodies and the complete mIHC kit?
The five validated primaries are stocked and orderable directly from the product pages above. The TSA amplification kit, detection reagents, auxiliaries, and consumables are configured per project — request a quote and a BioHippo specialist will scope the full run.
References
- van de Wetering M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–945. doi:10.1016/j.cell.2015.03.053
- Yu X, et al. Application of tyramide signal amplification-based multiplex immunohistochemistry/immunofluorescence: a bibliometrics analysis. Front Oncol. 2025;14:1473414. doi:10.3389/fonc.2024.1473414
- Shimokawa M, et al. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature. 2017;545(7653):187–192. doi:10.1038/nature22081
- Mo S, et al. Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy. Adv Sci. 2022;9(31):e2204097. doi:10.1002/advs.202204097
For Research Use Only (RUO). Not for use in diagnostic or therapeutic procedures. Primary antibodies manufactured by UcallM Biosciences Inc. Marker functions summarize common research use; marker–fluorophore assignments, channels, and dilutions reflect a representative validated run and should be confirmed and optimized for your samples. Confirm species reactivity, application, and recommended dilution on each product page before purchase. Citations retrieved and verified via PubMed.
